Krabbe Disease Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | AlaMab Therapeutics, Zentalis Pharmaceuticals, Isofol Medical, Merck, Eisai Co Ltd, Jiangsu Hengrui M

Krabbe Disease Pipeline constitutes 8+ key companies continuously working towards developing 8+ Krabbe Disease treatment therapies, analyzes DelveInsight.

Krabbe Disease Overview:

Krabbe disease encompasses a range of conditions, from infantile-onset disease (characterized by symptoms such as extreme irritability, spasticity, and developmental delay before 12 months of age) to later-onset disease (where symptoms appear after 12 months, potentially as late as the seventh decade of life). Historically, 85%-90% of symptomatic individuals diagnosed through enzyme activity alone have had infantile-onset Krabbe disease, with 10%-15% having later-onset. However, newborn screening (NBS) has indicated that the prevalence of later-onset Krabbe disease may be higher than previously believed. Infantile-onset Krabbe disease typically involves normal development initially, followed by rapid and severe neurological decline, with an average life expectancy of 24 months (ranging from 8 months to 9 years). Later-onset Krabbe disease presents more variably and its progression is less predictable.

Request for a detailed insights report on Krabbe Disease pipeline insights @ https://www.delveinsight.com/report-store/krabbe-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Krabbe Disease Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Krabbe Disease Therapeutics Market.

Key Takeaways from the Krabbe Disease Pipeline Report

DelveInsight's Krabbe Disease pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for Krabbe Disease treatment.
In January 2025, The FDA awarded breakthrough therapy designation (BTD) to GSK5764227 (GSK'227) for treating adult patients with relapsed or refractory Krabbe Disease who have experienced disease progression after receiving at least two previous treatment regimens.
Key Krabbe Disease companies such as Forge Biologics, Passage Bio, Sanbio, Polaryx, Gain Therapeutics, and others are evaluating new drugs for Krabbe Disease to improve the treatment landscape.
Promising Krabbe Disease pipeline therapies in various stages of development include FBX-101, PBKR03, and others.

Krabbe Disease Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Krabbe Disease Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Krabbe Disease treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Krabbe Disease market.

Download our free sample page report on Krabbe Disease pipeline insights @ https://www.delveinsight.com/sample-request/krabbe-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Krabbe Disease Emerging Drugs

FBX-101: Forge Biologics
PBKR03: Passage Bio

Krabbe Disease Companies

There are around eight key companies developing therapies for Krabbe Disease. Among them, Passage Bio has drug candidates for Krabbe Disease in the most advanced stage, specifically Phase I/II.

DelveInsight's report covers around 22+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Krabbe Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Krabbe Disease Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Krabbe Disease Therapies and Key Companies: Krabbe Disease Clinical Trials and advancements @ https://www.delveinsight.com/report-store/krabbe-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Krabbe Disease Pipeline Therapeutic Assessment
• Krabbe Disease Assessment by Product Type
• Krabbe Disease By Stage
• Krabbe Disease Assessment by Route of Administration
• Krabbe Disease Assessment by Molecule Type

Download Krabbe Disease Sample report to know in detail about the Krabbe Disease treatment market @ Krabbe Disease Therapeutic Assessment @ https://www.delveinsight.com/sample-request/krabbe-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Krabbe Disease Current Treatment Patterns
4. Krabbe Disease - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Krabbe Disease Late-Stage Products (Phase-III)
7. Krabbe Disease Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Krabbe Disease Discontinued Products
13. Krabbe Disease Product Profiles
14. Krabbe Disease Key Companies
15. Krabbe Disease Key Products
16. Dormant and Discontinued Products
17. Krabbe Disease Unmet Needs
18. Krabbe Disease Future Perspectives
19. Krabbe Disease Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Krabbe Disease Pipeline Reports Offerings: https://www.delveinsight.com/report-store/krabbe-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

This release was published on openPR.